{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:21:06Z","timestamp":1779909666817,"version":"3.53.1"},"reference-count":110,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijtb.2025.03.006","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T03:58:28Z","timestamp":1741665508000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting Mycobacterium tuberculosis F420-dependent dehydrogenases for new anti-tubercular drug discovery"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-012X","authenticated-orcid":false,"given":"Adewale V.","family":"Aderemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Snee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2025.03.006_bib1","series-title":"Global Tuberculosis Report 2020","year":"2020"},{"key":"10.1016\/j.ijtb.2025.03.006_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0029-5582(59)90143-9","article-title":"Global tuberculosis report 2022","volume":"13","author":"Moshinsky","year":"1959","journal-title":"Nucl Phys"},{"key":"10.1016\/j.ijtb.2025.03.006_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pathogens11101101","article-title":"Tuberculosis in an aging world","volume":"11","author":"Olmo-Font\u00e1nez","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.ijtb.2025.03.006_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4046\/trd.2015.78.2.47","article-title":"Diagnosis and treatment of extrapulmonary tuberculosis","volume":"78","author":"Lee","year":"2015","journal-title":"Tuberc Respir Dis"},{"key":"10.1016\/j.ijtb.2025.03.006_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002786","article-title":"Host-response-based gene signatures for tuberculosis diagnosis: a systematic comparison of 16 signatures","volume":"16","author":"Warsinske","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijtb.2025.03.006_bib6","series-title":"High-priority Target Product Profiles for New Tuberculosis Diagnostics: Report of a Consensus Meeting 2014","year":"2014"},{"key":"10.1016\/j.ijtb.2025.03.006_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7861\/clinmedicine.14-3-279","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges","volume":"14","author":"G\u00fcnther","year":"2014","journal-title":"Clin Med"},{"key":"10.1016\/j.ijtb.2025.03.006_bib8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.abb.2009.07.011","article-title":"The Mycobacterium tuberculosis cytochrome P450 system","volume":"493","author":"Ouellet","year":"2010","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.ijtb.2025.03.006_bib9","series-title":"|Global Tuberculosis Report 2018","year":"2018"},{"key":"10.1016\/j.ijtb.2025.03.006_bib10","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1007\/s00253-019-09697-z","article-title":"Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?","volume":"103","author":"Ugalde","year":"2019","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tube.2017.04.008","article-title":"Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: rifampicin and pyrazinamide in the post whole genome sequencing era","volume":"105","author":"Nusrath Unissa","year":"2017","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijtb.2025.03.006_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/tuld.1998.0002","article-title":"Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update","volume":"79","author":"Ramaswamy","year":"1998","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.ijtb.2025.03.006_bib13","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nm0696-662","article-title":"Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus","volume":"2","author":"Scorpio","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.ijtb.2025.03.006_bib14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1742-4658.2007.06241.x","article-title":"Characterization of Mycobacterium tuberculosis nicotinamidase\/pyrazinamidase","volume":"275","author":"Zhang","year":"2008","journal-title":"FEBS J"},{"key":"10.1016\/j.ijtb.2025.03.006_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","article-title":"Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis","volume":"45","author":"Unissa","year":"2016","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/03602532.2018.1559184","article-title":"Novel insights into the pharmacometabonomics of first-line tuberculosis drugs relating to metabolism, mechanism of action and drug-resistance","volume":"50","author":"Du Preez","year":"2018","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.ijtb.2025.03.006_bib17","first-page":"227","article-title":"Quemard A.,et al. inhA, a gene encoding a target for isoniazid and ethionamide in","volume":"263","author":"Banerjee","year":"1994","journal-title":"Mycobacterium tuberculosis. Science."},{"key":"10.1016\/j.ijtb.2025.03.006_bib18","doi-asserted-by":"crossref","unstructured":"Mdluli K., Slayden., R.A., Zhu Y., et al. Inhibition of a Mycobacterium tuberculosis \u03b2-Ketoacyl ACP synthase by isoniazid. Science. 1998;280:1607\u20131610.","DOI":"10.1126\/science.280.5369.1607"},{"key":"10.1016\/j.ijtb.2025.03.006_bib19","first-page":"12","article-title":"Sadeghifard N.,et al. Mechanism of action, resistance, synergism, and clinical implications of delamanid against multidrug-resistant","author":"Khoshnood","year":"2021","journal-title":"Mycobacterium tuberculosis. Front Microbiol."},{"key":"10.1016\/j.ijtb.2025.03.006_bib20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.4155\/fmc.10.207","article-title":"The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies","volume":"2","author":"Denny","year":"2010","journal-title":"Future Med Chem"},{"key":"10.1016\/j.ijtb.2025.03.006_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jyp.2013.12.002","article-title":"Bedaquiline - the first ATP synthase inhibitor against multi drug resistant tuberculosis","volume":"5","author":"Lakshmanan","year":"2013","journal-title":"J Young Pharm"},{"key":"10.1016\/j.ijtb.2025.03.006_bib22","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/prot.21376","article-title":"A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910","volume":"67","author":"De Jonge","year":"2007","journal-title":"Proteins Struct Funct Genet"},{"key":"10.1016\/j.ijtb.2025.03.006_bib23","first-page":"1","article-title":"Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in mycobacterium tuberculosis","volume":"65","author":"Rifat","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2025.03.006_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/glycob\/11.9.107R","article-title":"Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis","volume":"11","author":"Crick","year":"2001","journal-title":"Glycobiology"},{"key":"10.1016\/j.ijtb.2025.03.006_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2023.1194923","article-title":"Mycobacterium tuberculosis cell-wall and antimicrobial peptides: a mission impossible?","volume":"14","author":"Jacobo-Delgado","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/app10072278","article-title":"Mycobacterial cell wall: a source of successful targets for old and new drugs","volume":"10","author":"Vilch\u00e8ze","year":"2020","journal-title":"Appl Sci"},{"key":"10.1016\/j.ijtb.2025.03.006_bib27","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/femsre\/fuz016","article-title":"Cell wall peptidoglycan in Mycobacterium tuberculosis: an Achilles\u2019 heel for the TB-causing pathogen","volume":"43","author":"Maitra","year":"2019","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.ijtb.2025.03.006_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.bi.64.070195.000333","article-title":"The envelope of mycobacteria","volume":"64","author":"Brennan","year":"1995","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.ijtb.2025.03.006_bib29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.micpath.2010.07.004","article-title":"Roles of PE_PGRS family in mycobacterium tuberculosis pathogenesis and novel measures against tuberculosis","volume":"49","author":"Tian","year":"2010","journal-title":"Microb Pathog"},{"key":"10.1016\/j.ijtb.2025.03.006_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/microorganisms7030070","article-title":"Mmpl proteins in physiology and pathogenesis of M. tuberculosis","volume":"7","author":"Melly","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijtb.2025.03.006_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12915-017-0471-6","article-title":"Phthiocerol dimycocerosates promote access to the cytosol and intracellular burden of Mycobacterium tuberculosis in lymphatic endothelial cells","volume":"16","author":"Lerner","year":"2018","journal-title":"BMC Biol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib32","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1073\/pnas.1700062114","article-title":"MmpL3 is the flippase for mycolic acids in mycobacteria","volume":"114","author":"Xu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijtb.2025.03.006_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nature12799","article-title":"Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids","volume":"505","author":"Cambier","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ijtb.2025.03.006_bib34","first-page":"537","volume":"393","author":"Cole","year":"1998","journal-title":"Deciphering the biology of Mycobacterium tuberculosis. nature."},{"key":"10.1016\/j.ijtb.2025.03.006_bib35","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1128\/JB.00425-10","article-title":"Unexpected abundance of coenzyme F420-dependent enzymes in Mycobacterium tuberculosis and other actinobacteria","volume":"192","author":"Selengut","year":"2010","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib36","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1128\/AEM.02500-16","article-title":"The redox cofactor F420 protects mycobacteria from diverse antimicrobial compounds and mediates a reductive detoxification system","volume":"82","author":"Jirapanjawat","year":"2016","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2017.01000","article-title":"Mycobacterial F420H2-dependent reductases promiscuously reduce diverse compounds through a common mechanism substrate promiscuity of F420 H2-dependent reductases","volume":"8","author":"Greening","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib38","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/pro.2975","article-title":"Rv2074 is a novel F420 H2-dependent biliverdin reductase in Mycobacterium tuberculosis","volume":"25","author":"Ahmed","year":"2016","journal-title":"Protein Sci"},{"key":"10.1016\/j.ijtb.2025.03.006_bib39","doi-asserted-by":"crossref","first-page":"17531","DOI":"10.1074\/jbc.M801854200","article-title":"Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding","volume":"283","author":"Bashiri","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijtb.2025.03.006_bib40","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1128\/JB.01035-15","article-title":"F420 H2 is required for phthiocerol dimycocerosate synthesis in mycobacteria","volume":"198","author":"Purwantini","year":"2016","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1371\/journal.pone.0081985","article-title":"Rv0132c of Mycobacterium tuberculosis encodes a coenzyme F420-dependent hydroxymycolic acid dehydrogenase","volume":"8","author":"Purwantini","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijtb.2025.03.006_bib42","article-title":"Tat-dependent translocation of an F420-binding protein of","volume":"7","author":"Bashiri","year":"2012","journal-title":"Mycobacterium tuberculosis. PLoS One."},{"key":"10.1016\/j.ijtb.2025.03.006_bib43","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.bbamem.2007.07.015","article-title":"Sec- and Tat-mediated protein secretion across the bacterial cytoplasmic membrane-Distinct translocases and mechanisms","volume":"1778","author":"Natale","year":"2008","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"key":"10.1016\/j.ijtb.2025.03.006_bib44","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/pro.2645","article-title":"Molecular insights into the binding of coenzyme F420 to the conserved protein Rv1155 from Mycobacterium tuberculosis","volume":"24","author":"Mashalidis","year":"2015","journal-title":"Protein Sci"},{"key":"10.1016\/j.ijtb.2025.03.006_bib45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/MMBR.00070-15","article-title":"Mohamed A.E.,et al. Physiology, biochemistry, and applications of F420- and Fo-dependent redox reactions","volume":"80","author":"Greening","year":"2016","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.ijtb.2025.03.006_bib46","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/mmi.12127","article-title":"A novel F420-dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents","volume":"87","author":"Gurumurthy","year":"2013","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1021\/ar00127a004","article-title":"Naturally occurring 5-deazaflavin coenzymes: biological redox roles","volume":"19","author":"Walsh","year":"1986","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.ijtb.2025.03.006_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2017.01902","article-title":"Sparling R.,et al. Cofactor tail length modulates catalysis of bacterial F420-dependent oxidoreductases","volume":"8","author":"Ney","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/JB.00375-18","article-title":"Coenzyme F420-dependent glucose-6-phosphate dehydrogenase-coupled polyglutamylation of coenzyme F420 in mycobacteria","volume":"200","author":"Purwantini","year":"2018","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib50","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2958.2010.07358.x","article-title":"A new role for coenzyme F420 in aflatoxin reduction by soil mycobacteria","volume":"78","author":"Graham","year":"2010","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-09534-x","article-title":"A revised biosynthetic pathway for the cofactor F420 in prokaryotes","volume":"10","author":"Bashiri","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijtb.2025.03.006_bib52","doi-asserted-by":"crossref","first-page":"18173","DOI":"10.1021\/ja307762b","article-title":"Biosynthesis of F0, precursor of the F420 cofactor, requires a unique two radical-SAM domain enzyme and tyrosine as substrate","volume":"134","author":"Decamps","year":"2012","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ijtb.2025.03.006_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-01224-3","article-title":"Improved production of the non-native cofactor F420 in Escherichia coli","volume":"11","author":"Shah","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijtb.2025.03.006_bib54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00203-004-0675-3","article-title":"F420H2 oxidase (FprA) from Methanobrevibacter arboriphilus, a coenzyme F420-dependent enzyme involved in O2 detoxification","volume":"182","author":"Seedorf","year":"2004","journal-title":"Arch Microbiol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib55","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jsb.2019.03.006","article-title":"The crystal structure of Rv2991 from Mycobacterium tuberculosis: an F420 binding protein with unknown function","volume":"206","author":"Benini","year":"2019","journal-title":"J Struct Biol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.str.2011.11.001","article-title":"Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824","volume":"20","author":"Cellitti","year":"2012","journal-title":"Structure"},{"key":"10.1016\/j.ijtb.2025.03.006_bib57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bbapap.2017.08.001","article-title":"Mechanistic insights into F420-dependent glucose-6-phosphate dehydrogenase using isotope effects and substrate inhibition studies","volume":"1866","author":"Oyugi","year":"2018","journal-title":"Biochim Biophys Acta, Proteins Proteomics"},{"key":"10.1016\/j.ijtb.2025.03.006_bib58","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s00253-016-8038-y","article-title":"Discovery and characterization of an F420-dependent glucose-6-phosphate dehydrogenase (Rh-FGD1) from Rhodococcus jostii RHA1","volume":"101","author":"Nguyen","year":"2017","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib59","article-title":"Keto-Mycolic acid-dependent pellicle formation confers tolerance to drug-sensitive","volume":"4","author":"Sambandan","year":"2013","journal-title":"Mycobacterium tuberculosis. mBio."},{"key":"10.1016\/j.ijtb.2025.03.006_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pro.2584","article-title":"Production of recombinant proteins in Mycobacterium smegmatis for structural and functional studies","volume":"24","author":"Bashiri","year":"2015","journal-title":"Protein Sci"},{"key":"10.1016\/j.ijtb.2025.03.006_bib61","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1128\/JB.180.8.2212-2219.1998","article-title":"Molecular analysis of the gene encoding F420-dependent glucose-6- phosphate dehydrogenase from Mycobacterium smegmatis","volume":"180","author":"Purwantini","year":"1998","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib62","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0958-1669(99)00003-8","article-title":"Recombinant protein expression in Escherichia coli","volume":"10","author":"Baneyx","year":"1999","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib63","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1074\/mcp.M113.032623","article-title":"Exploration of novel cellular and serological antigen biomarkers in the orfeome of","volume":"13","author":"Liu","year":"2014","journal-title":"Mycobacterium tuberculosis. Mol Cell Proteomics."},{"key":"10.1016\/j.ijtb.2025.03.006_bib64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.pep.2007.08.015","article-title":"A new Gateway\u00ae vector and expression protocol for fast and efficient recombinant protein expression in Mycobacterium smegmatis","volume":"57","author":"Goldstone","year":"2008","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.ijtb.2025.03.006_bib65","doi-asserted-by":"crossref","first-page":"106650","DOI":"10.1016\/j.pep.2024.106650","article-title":"Expression and purification of Mycobacterium tuberculosis F420 -dependent glucose-6-phosphate dehydrogenase enzyme using Escherichia coli","volume":"228","author":"Aderemi","year":"2025","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.ijtb.2025.03.006_bib66","doi-asserted-by":"crossref","first-page":"33087","DOI":"10.1039\/C8RA06237D","article-title":"A GFP-strategy for efficient recombinant protein overexpression and purification in Mycobacterium smegmatis","volume":"8","author":"Radhakrishnan","year":"2018","journal-title":"RSC Adv"},{"key":"10.1016\/j.ijtb.2025.03.006_bib67","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1021\/bi400351h","article-title":"Characterization of an aldolase-dehydrogenase complex from the cholesterol degradation pathway of Mycobacterium tuberculosis","volume":"52","author":"Carere","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijtb.2025.03.006_bib68","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ja.2007.48","article-title":"Lariatins, novel anti-mycobacterial peptides with a lasso structure, produced by Rhodococcus jostii K01-B0171","volume":"60","author":"Iwatsuki","year":"2007","journal-title":"J. Antibiot. (Tokyo)."},{"key":"10.1016\/j.ijtb.2025.03.006_bib69","doi-asserted-by":"crossref","first-page":"15582","DOI":"10.1073\/pnas.0607048103","article-title":"The complete genome of Rhodococcus sp. RHA1 provides insights into a catabolic powerhouse","volume":"103","author":"McLeod","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijtb.2025.03.006_bib70","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2164-13-120","article-title":"Comparative analysis of mycobacterium and related actinomycetes yields insight into the evolution of Mycobacterium tuberculosis pathogenesis","volume":"13","author":"McGuire","year":"2012","journal-title":"BMC Genom"},{"key":"10.1016\/j.ijtb.2025.03.006_bib71","first-page":"369","article-title":"Temperature stability of proteins essential for the intracellular survival of","volume":"418","author":"Lack","year":"2009","journal-title":"Mycobacterium tuberculosis. Biochem J."},{"key":"10.1016\/j.ijtb.2025.03.006_bib72","first-page":"70","article-title":"Optimization of Mycobacterium tuberculosis DHFR production from recombinant Saccharomyces cerevisiae","volume":"2","author":"Raju","year":"2013","journal-title":"Int. J. Curr. Microbiol. App. Sci"},{"key":"10.1016\/j.ijtb.2025.03.006_bib73","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1128\/AAC.46.11.3362-3369.2002","article-title":"Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase","volume":"46","author":"Gerum","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2025.03.006_bib74","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.celrep.2014.11.023","article-title":"Mycobacterium tuberculosis proteome microarray for global studies of protein function and immunogenicity","volume":"9","author":"Deng","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.ijtb.2025.03.006_bib75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1472-6750-11-27","article-title":"Improved mycobacterial protein production using a Mycobacterium smegmatis groEL1\u0394C expression strain","volume":"11","author":"Noens","year":"2011","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib76","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1128\/iai.61.1.260-267.1993","article-title":"Expression of the Mycobacterium tuberculosis 19-kilodalton antigen in mycobacterium-smegmatis - immunological analysis and evidence of glycosylation","volume":"61","author":"Garbe","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.ijtb.2025.03.006_bib77","first-page":"1453","article-title":"Linked references are available on JSTOR for this article\u202f: the Complete Genome Sequence of Escherichia col K-i 2","volume":"277","author":"Blattner","year":"1997","journal-title":"Am. Assoc. Adv. Sci."},{"key":"10.1016\/j.ijtb.2025.03.006_bib78","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMsr1512438","article-title":"Twenty years of global surveillance of antituberculosis-drug resistance","volume":"375","author":"Zignol","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijtb.2025.03.006_bib79","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/2472555218773034","article-title":"Using fragment-based approaches to discover new antibiotics","volume":"23","author":"Lamoree","year":"2018","journal-title":"SLAS Discov."},{"key":"10.1016\/j.ijtb.2025.03.006_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmolb.2020.00001","article-title":"Application of fragment-based drug discovery to versatile targets","volume":"7","author":"Li","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.ijtb.2025.03.006_bib81","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrd.2016.109","article-title":"Twenty years on: the impact of fragments on drug discovery","volume":"15","author":"Erlanson","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijtb.2025.03.006_bib82","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10858-013-9740-z","article-title":"Fragment-based drug discovery using NMR spectroscopy","volume":"56","author":"Harner","year":"2013","journal-title":"J Biomol NMR"},{"key":"10.1016\/j.ijtb.2025.03.006_bib83","first-page":"1765","article-title":"Metamorphic rocks of the causes of southeastern Lhasa terrane and the Mesozoic - cenozoic orogeny","volume":"28","author":"Dong","year":"2012","journal-title":"Acta Petrol Sin"},{"key":"10.1016\/j.ijtb.2025.03.006_bib84","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1359-6446(03)02765-X","article-title":"PET and knockout mice in drug discovery","volume":"8","author":"N\u00e5gren","year":"2003","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ijtb.2025.03.006_bib85","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1359-6446(99)01451-8","article-title":"Computational methods for the prediction of \u2018drug-likeness\u2019","volume":"5","author":"Clark","year":"2000","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ijtb.2025.03.006_bib86","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrd3926-c1","article-title":"The \u2018rule of three\u2019 for fragment-based drug discovery: where are we now?","volume":"12","author":"Jhoti","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijtb.2025.03.006_bib87","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijtb.2025.03.006_bib88","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.ijtb.2025.03.006_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijtb.2025.03.006_bib90","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/2472555220916168","article-title":"Applied biophysical methods in fragment-based drug discovery","volume":"25","author":"Coyle","year":"2020","journal-title":"SLAS Discov."},{"key":"10.1016\/j.ijtb.2025.03.006_bib91","first-page":"243","article-title":"Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma","volume":"4","author":"Fisher","year":"2012","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ijtb.2025.03.006_bib92","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1634\/theoncologist.2018-0295","article-title":"FDA approval summary: vemurafenib for the treatment of patients with erdheim-chester disease with the BRAF V600 mutation","volume":"23","author":"Oneal","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ijtb.2025.03.006_bib93","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.2147\/CMAR.S180724","article-title":"Evaluating venetoclax and its potential in treatment-na\u00efve acute myeloid leukemia","volume":"11","author":"Knight","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ijtb.2025.03.006_bib94","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","article-title":"Erdafitinib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ijtb.2025.03.006_bib95","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40268-020-00314-3","article-title":"Pexidartinib (TURALIOTM): the first FDA-indicated systemic treatment for tenosynovial giant cell tumor","volume":"20","author":"Monestime","year":"2020","journal-title":"Drugs R&D"},{"key":"10.1016\/j.ijtb.2025.03.006_bib96","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/DDDT.S253232","article-title":"Pexidartinib, a novel small molecule csf-1r inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development","volume":"14","author":"Benner","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ijtb.2025.03.006_bib97","article-title":"NMR methods to characterize protein-ligand interactions","volume":"14","author":"Maity","year":"2019","journal-title":"Nat Prod Commun"},{"key":"10.1016\/j.ijtb.2025.03.006_bib98","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/cphc.201701253","article-title":"Investigating protein\u2013ligand interactions by solution nuclear magnetic resonance spectroscopy","volume":"19","author":"Becker","year":"2018","journal-title":"ChemPhysChem"},{"key":"10.1016\/j.ijtb.2025.03.006_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnmrs.2013.02.001","article-title":"Using chemical shift perturbation to characterise ligand binding","volume":"73","author":"Williamson","year":"2013","journal-title":"Prog Nucl Magn Reson Spectrosc"},{"key":"10.1016\/j.ijtb.2025.03.006_bib100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1432-1033.1974.tb03774.x","article-title":"A study by the hydrogen-exchange method of the complex formed between the basic pancreatic trypsin inhibitor and trypsin","volume":"48","author":"Pershina","year":"1974","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.ijtb.2025.03.006_bib101","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10858-014-9848-9","article-title":"Comparison of the sensitivities of WaterLOGSY and saturation transfer difference NMR experiments","volume":"60","author":"Antanasijevic","year":"2014","journal-title":"J Biomol NMR"},{"key":"10.1016\/j.ijtb.2025.03.006_bib102","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/138920012798918372","article-title":"Is there a relationship between the substrate preferences and structural flexibility of cytochromes P450?","volume":"13","author":"Otyepka","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ijtb.2025.03.006_bib103","series-title":"Biophysical and structural studies of novel F420-dependent oxidoreductases in Mycobacterium tuberculosis","author":"Mashalidis","year":"2012"},{"key":"10.1016\/j.ijtb.2025.03.006_bib104","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/resp.13393","article-title":"Drug resistance mechanisms and drug susceptibility testing for tuberculosis","volume":"23","author":"Miotto","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.ijtb.2025.03.006_bib105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4161\/viru.23724","article-title":"Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm","volume":"4","author":"Soto","year":"2013","journal-title":"Virulence"},{"key":"10.1016\/j.ijtb.2025.03.006_bib106","doi-asserted-by":"crossref","first-page":"17531","DOI":"10.1074\/jbc.M801854200","article-title":"Crystal structures of F420-depedendent Glucose-6-phosphate Dehydrogenase FGD1 Involved in the Activation of the Anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding","volume":"283","author":"Bashiri","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijtb.2025.03.006_bib107","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev.micro.60.080805.142212","article-title":"The bacterial twin-arginine translocation pathway","volume":"60","author":"Lee","year":"2006","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-695X.2011.00831.x","article-title":"Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis","volume":"63","author":"da Silva","year":"2011","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.ijtb.2025.03.006_bib109","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2174\/1568026618666180813152921","article-title":"Structure-based drug design strategies and challenges","volume":"18","author":"Wang","year":"2018","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.ijtb.2025.03.006_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2023.115569","article-title":"Recent advances in Fragment- based strategies against tuberculosis","volume":"258","author":"Villemagne","year":"2023","journal-title":"Eur J Med Chem"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570725000836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570725000836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:41:33Z","timestamp":1773322893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570725000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0019570725000836"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2025.03.006","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Mycobacterium tuberculosis F420-dependent dehydrogenases for new anti-tubercular drug discovery","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2025.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Tuberculosis Association of India. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}